Skip to Content

New Drug Approvals Archive - April 2003

April 2003

Iprivask (desirudin) Injection

Date of Approval: April 4, 2003
Company: Aventis Pharmaceuticals, Inc
Treatment for: Deep Vein Thrombosis -- Prophylaxis

Iprivask (desirudin) is a specific inhibitor of human thrombin indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in patients undergoing elective hip replacement surgery.

Factive (gemifloxacin) Tablets

Date of Approval: April 4, 2003
Company: LG Life Sciences, Ltd
Treatment for: Bacterial Infection

Factive (gemifloxacin) is a fluoroquinolone antibiotics indicated for the treatment of community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis.

Vigamox (moxifloxacin) Ophthalmic Solution

Date of Approval: April 15, 2003
Company: Alcon
Treatment for: Bacterial Conjunctivitis

Vigamox (moxifloxacin) is a fourth generation fluoroquinilone antibiotic indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of bacteria.

Fabrazyme (agalsidase beta)

Date of Approval: April 24, 2003
Company: Genzyme Corp
Treatment for: Fabry Disease

Fabrazyme (agalsidase beta) is a recombinant form of human alpha-galactosidase A, administered intravenously for the treatment of Fabry Disease.

Aldurazyme (laronidase)

Date of Approval: April 30, 2003
Company: Biomarin Pharmaceutical
Treatment for: Mucopolysaccharidosis Type I

Aldurazyme (laronidase) is recombinant human alpha-L-iduronidaseis indicated for the treatment of mucopolysaccharidosis I (MPS I).

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.